9 hours ago
Novo Nordisk's CagriSema Shot Tied to Greater Weight Loss at Lower Doses
Novo Nordisk A/S's next-generation obesity shot CagriSema helped patients lose weight in large studies despite only about three-quarters of the patients ever making it to the highest dose. Surprisingly, patients who chose to stick with a lower dose lost more weight on average.
The studies allowed patients to stop at lower doses of the drug, an unusual option in a trial. Researchers presenting new data Sunday at the American Diabetes Association meeting in Chicago say the findings offer clues as to how the drug would be used in real life. There's a group of people who respond very well to this medicine, said Timothy Garvey, director of the Diabetes Research Center at the University of Alabama at Birmingham, who helped lead the trials.
